How do I check that two KP lots of retatrutide agree on content assay?

Concretely: KP · retatrutide.

I have a result I cannot explain, and I would rather diagnose it than guess.

I have checked the obvious explanations and eliminated the two easiest ones.

What is the differential here, and which test discriminates between the options?

Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

If testing multiple vials, state how many you tested and why you chose those vials.

The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

On the detail: under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

On the detail: the failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

edited 7 Apr 2025 by helena_vidmar — fixed an arithmetic slip in the third paragraph

Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.